PMID- 19013511
OWN - NLM
STAT- MEDLINE
DCOM- 20090331
LR  - 20171116
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 121
IP  - 1
DP  - 2009 Jan 12
TI  - KIOM-79 prevents apoptotic cell death and AGEs accumulation in retinas of 
      diabetic db/db mice.
PG  - 171-4
LID - 10.1016/j.jep.2008.09.036 [doi]
AB  - AIM OF THE STUDY: KIOM-79 retards the development of diabetic nephropathy in 
      animal models of type 1 and type 2 diabetes. In this study, we evaluated whether 
      KIOM-79 could prevent apoptotic cell death and advanced glycation end products 
      (AGEs) accumulation in the retinas of diabetic db/db mice. MATERIAL AND METHODS: 
      Mice were treated orally with KIOM-79 (150 mg/kg body weight) once daily for 12 
      weeks. Levels of retinal ganglion cell death were measured by terminal dUTP 
      nick-end labeling (TUNEL) assay. In the retina, the activity of caspase-3 (a 
      marker of apoptosis) and the formation of AGEs were measured by 
      immunohistochemical staining. RESULTS: KIOM-79 reduced the number of 
      TUNEL-immunoreactive retinal cells. KIOM-79 attenuated caspase-3 expression and 
      AGEs accumulation in the retina. CONCLUSIONS: These data show that KIOM-79 can 
      prevent apoptosis in neuronal cells, AGEs accumulation in the retina, and retard 
      the development of diabetic retinopathy.
FAU - Sohn, Eun Jin
AU  - Sohn EJ
AD  - Department of Herbal Pharmaceutical Development, Korea Institute of Oriental 
      Medicine, 461-24 Jeonmin-dong, Yuseong-gu, Daejeon 305-811, Republic of Korea.
FAU - Kim, Young Sook
AU  - Kim YS
FAU - Kim, Chan-Sik
AU  - Kim CS
FAU - Lee, Yun Mi
AU  - Lee YM
FAU - Kim, Jin Sook
AU  - Kim JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081101
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Antioxidants)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (KIOM 79)
RN  - 0 (Plant Extracts)
RN  - EC 3.4.22.- (Casp3 protein, mouse)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antioxidants/pharmacology/*therapeutic use
MH  - Apoptosis/*drug effects
MH  - Caspase 3/metabolism
MH  - Cell Death/drug effects
MH  - Diabetes Mellitus, Experimental/metabolism/pathology/prevention & control
MH  - Diabetic Retinopathy/metabolism/pathology/*prevention & control
MH  - Disease Models, Animal
MH  - Glycation End Products, Advanced/*antagonists & inhibitors/metabolism
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - Retina/*drug effects/metabolism/pathology
MH  - Retinal Ganglion Cells/metabolism/pathology
EDAT- 2008/11/18 09:00
MHDA- 2009/04/01 09:00
CRDT- 2008/11/18 09:00
PHST- 2008/04/21 00:00 [received]
PHST- 2008/09/16 00:00 [revised]
PHST- 2008/09/29 00:00 [accepted]
PHST- 2008/11/18 09:00 [pubmed]
PHST- 2009/04/01 09:00 [medline]
PHST- 2008/11/18 09:00 [entrez]
AID - S0378-8741(08)00551-5 [pii]
AID - 10.1016/j.jep.2008.09.036 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2009 Jan 12;121(1):171-4. doi: 10.1016/j.jep.2008.09.036. Epub 
      2008 Nov 1.